Johnson Matthey PLC (LON:JMAT - Get Free Report)'s stock price was up 29% during trading on Friday . The company traded as high as GBX 1,888 ($25.51) and last traded at GBX 1,792.32 ($24.22). Approximately 3,427,063 shares were traded during trading, an increase of 25% from the average daily volume of 2,743,881 shares. The stock had previously closed at GBX 1,389 ($18.77).
Johnson Matthey Price Performance
The stock's fifty day moving average price is GBX 1,319.16 and its 200-day moving average price is GBX 1,378.49. The company has a debt-to-equity ratio of 62.73, a current ratio of 1.45 and a quick ratio of 0.76. The firm has a market cap of £2.86 billion, a price-to-earnings ratio of 29.06, a price-to-earnings-growth ratio of 49,242.50 and a beta of 0.95.
Johnson Matthey (LON:JMAT - Get Free Report) last issued its earnings results on Thursday, May 22nd. The company reported GBX 149.20 ($2.02) earnings per share for the quarter. Johnson Matthey had a return on equity of 4.49% and a net margin of 0.84%. Equities research analysts predict that Johnson Matthey PLC will post 173.4112903 EPS for the current fiscal year.
Johnson Matthey Increases Dividend
The company also recently announced a dividend, which was paid on Wednesday, April 16th. Shareholders of record on Thursday, April 10th were paid a GBX 32 ($0.43) dividend. The ex-dividend date was Thursday, April 10th. This represents a yield of 1.88%. This is an increase from Johnson Matthey's previous dividend of $22.00. Johnson Matthey's payout ratio is 130.84%.
Insider Activity at Johnson Matthey
In other news, insider Liam Condon bought 30 shares of the business's stock in a transaction that occurred on Wednesday, April 16th. The stock was acquired at an average cost of GBX 1,200 ($16.22) per share, for a total transaction of £360 ($486.49). Over the last quarter, insiders have acquired 75 shares of company stock valued at $99,927. 0.61% of the stock is currently owned by corporate insiders.
About Johnson Matthey
(
Get Free Report)
Johnson Matthey is a global leader in science that enables a cleaner and healthier world. With over 200 years of sustained commitment to innovation and technological breakthroughs, they improve the function, performance and safety of their customers' products. Their science has a global impact in areas such as low emission transport, pharmaceuticals, chemical processing and making the most efficient use of the planet's natural resources.
Featured Articles
Before you consider Johnson Matthey, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson Matthey wasn't on the list.
While Johnson Matthey currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
